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Abstract
Introduction: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen
receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects
the cell of origin of these tumors. However, approximately 20% of breast cancers that develop in BRCA1 carriers are
ER-positive (ER+); these cancers are more likely to develop as BRCA1 carriers age, suggesting that they may be
incidental and unrelated to BRCA1 deficiency. The purpose of this study was to compare the prevalence of loss of
heterozygosity due to loss of wild type (wt) BRCA1 in ER+ and ER- breast cancers that have occurred in BRCA1
carriers and to determine whether age at diagnosis or any pathologic features or biomarkers predict for loss of wt
BRCA1 in these breast cancers.
Methods: Relative amounts of mutated and wt BRCA1 DNA were measured by quantitative polymerase chain
reaction performed on laser capture microdissected cancer cells from 42 ER+ and 35 ER- invasive breast cancers
that developed in BRCA1 carriers. BRCA1 gene methylation was determined on all cancers in which sufficient DNA
was available. Immunostains for cytokeratins (CK) 5/6, 14, 8 and 18, epidermal growth factor receptor and p53 were
performed on paraffin sections from tissue microarrays containing these cancers.
Results: Loss of wt BRCA1 was equally frequent in ER+ and ER- BRCA1-associated cancers (81.0% vs 88.6%,
respectively; P = 0.53). One of nine cancers tested that retained wt BRCA1 demonstrated BRCA1 gene methylation.
Age at diagnosis was not significantly different between first invasive ER+ BRCA1 breast cancers with and without
loss of wt BRCA1 (mean age 45.2 years vs 50.1 years, respectively; P = 0.51). ER+ BRCA1 cancers that retained wt
BRCA1 were significantly more likely than those that lost wt BRCA1 to have a low mitotic rate (odds ratio (OR), 5.16;
95% CI, 1.91 to ∞). BRCA1 cancers with loss of wt BRCA1 were more likely to express basal cytokeratins CK 5/6 or
14 (OR 4.7; 95% CI, 1.85 to ∞).
Conclusions: We found no difference in the prevalence of loss of wt BRCA1 between ER+ and ER- invasive BRCA1-
associated breast cancers. Our findings suggest that many of the newer therapies for BRCA1 breast cancers
designed to exploit the BRCA1 deficiency in these cancers may also be effective in ER+ cancers that develop in this
population.
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Sixty-four to 90% of breast cancers that occur in BRCA1
mutation carriers (BRCA1 carriers) are estrogen receptor-
negative (ER-), progesterone receptor-negative (PR-) and
lack HER2 protein overexpression and gene amplification,
so called “triple negative” breast cancers [1-8]. These
BRCA1-associated ER- tumors typically demonstrate
characteristic pathologic features which include high
grade ductal histology, a high mitotic rate, a prominent
lymphocytic infiltrate, pushing or circumscribed margins,
and geographic areas of necrosis or a central fibrotic
focus [3,9,10]. In addition, these tumors often express
“basal” biomarkers and cluster within the “basal-like”
group in gene expression profiling studies [7,11-13].
Since BRCA1 cancers are so often ER-, it has been
suggested that ER negativity is intrinsic to BRCA1 can-
cers and reflects the cell of origin of these tumors [14].
Preclinical models suggest that BRCA1 can transcrip-
tionally induce ER gene expression and that loss of
BRCA1 function is accompanied by loss of ER expres-
sion [15-17]. However, approximately 10 to 36% of
breast cancers that occur in BRCA1 carriers are estrogen
receptor-positive (ER+) [4,6,8,18,19]. Further, as BRCA1
carriers age, they are increasingly more likely to develop
an ER+ breast cancer [14,20] following the trend seen in
breast cancers that develop in the general population. It
has, therefore, been suggested that ER+ BRCA1-asso-
ciated breast cancers may actually be incidental or
sporadic rather than caused by a complete loss of
BRCA1 function.
We have previously shown that the pathologic features
of ER+ invasive breast cancers that arise in BRCA1 car-
riers are significantly different than age-matched spora-
dic ER+ breast cancers in non-mutation carriers. When
compared to sporadic ER+ cancers, ER+ BRCA1-asso-
ciated cancers are more often of invasive ductal type
and exhibit a high mitotic rate [20]. With the develop-
ment of treatments such as poly(ADP-ribose) polymer-
ase (PARP) inhibitors that are targeted to the specific
defects in DNA repair pathways which exist in BRCA1
deficient cancers [21], it is important to determine
whether ER+ breast cancers that develop in BRCA1
mutation carriers are incidental (that is, not directly
related to the BRCA1 mutation/BRCA1 dysfunction) or
if they are mutation-related in order to determine
whether such BRCA1-targeted therapies might be effec-
tive in this population.
One way to address this issue is to analyze ER+ can-
cers that arise in BRCA1 mutation carriers for loss of
the wild type (wt) BRCA1 allele. Several recent studies
evaluating the prevalence of loss of heterozygosity
(LOH) in BRCA1-associated breast cancers have noted
that 50 to 90% of these cancers show LOH, with loss of
wt BRCA1 [22-24]. However, none of these studies was
designed to specifically evaluate loss of wt BRCA1 in
relation to ER status in BRCA1-associated cancers.
Therefore, we undertook a study to 1) determine the
prevalence of loss of heterozygosity with loss of the wt
BRCA1 allele in ER+ cancers from BRCA1 mutation car-
riers and compare it to that found in ER- BRCA1-asso-
ciated cancers; and 2) determine whether any clinical
factors (that is, age at diagnosis), pathologic features or
biomarkers predict for loss of wt BRCA1 in BRCA1-
associated breast cancers.
Materials and methods
A series of 51 ER+ and 47 ER- invasive breast cancers
was assembled from 88 women with deleterious BRCA1
germ-line mutations who had undergone genetic testing
at five high risk genetic programs.
Age at diagnosis of the breast cancer and determina-
tion of whether the cancer was a first or subsequent
cancer for the patient was determined from medical
record review. Specific BRCA1 mutations were con-
firmed by review of genetic test reports.
Histologic sections of BRCA1-associated ER- and ER+
breast cancers were reviewed by the study pathologists
blinded to the ER status of the tumor prior to the deter-
mination of LOH status. Each cancer was scored for the
following pathologic features: histologic type; Notting-
ham combined histologic grade, with each of the three
components of grade (that is, tubule formation, nuclear
grade and mitotic rate) recorded separately; presence of
geographic necrosis or fibrotic focus; extent of lympho-
cytic infiltrate; and tumor margin characteristics (inva-
sive or pushing).
Information regarding ER, PR and HER2 status,
assessed as part of the routine clinical evaluation, was
abstracted from institutional pathology reports. When
information regarding the ER, PR or HER2 status for
BRCA1 tumors was missing from the pathology report,
paraffin blocks were re-cut and sections were immunos-
tained for ER (SP1 antibody, Neomarkers, Fremont, CA,
USA), PR (PgR 636 antibody, Dako, Carpinteria, CA,
USA) and HER2 (A085 antibody, Dako). For ER-
tumors, ER expression was re-evaluated if the pathology
report did not state that an appropriately staining inter-
nal positive control was present. Similarly, ER+ tumors
with reports stating “faint” or “low” ER staining were re-
evaluated for ER expression. If greater than 1% of breast
cancer cells stained for ER, the tumor was considered
ER+. If fluorescence in situ hybridization (FISH) for
HER2 was available for a cancer, this result was used
rather than the IHC result.
Tissue microarrays were constructed by obtaining
three 0.6 mm cores from the formalin-fixed paraffin
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them in recipient paraffin blocks. Slides cut from the
TMAs were immunostained for cytokeratin (CK) 5/6
(D5/16B4 antibody, Dako), CK14 (LL02 antibody, Neo-
markers), CK7/8 (Cam5.2 antibody, BD Biosciences, San
Jose, CA, USA), CK18 (DC10 antibody, Dako) and CK19
(RCK108 antibody, Dako) as well as for EGFR (EGFR
pharmDX kit, Dako) and p53 (DO-7 antibody, Dako).
This study was approved by the institutional review
boards of Dana Farber/Harvard Cancer Center and
North Shore Medical Center.
Assessment of BRCA1 LOH
Representative slides from each cancer were reviewed by
a study pathologist and areas of normal tissue as well as
invasive cancer were identified. Cells were isolated from
hematoxylin and eosin stained tissue sections by laser
capture microdissection. Approximately 2,000 pulses
were used for each microdissection. As higher levels of
normal cell contamination will reduce the proportion of
mutant allele that is measured in a tumor with true
LOH, for each tumor we attempted at least two micro-
dissections performed at the same general region. For
each case, an area of normal non-tumor tissue present
in the same block as the cancer was microdissected to
obtain germline DNA. The microdissected cells were
lysed to release DNA by overnight digestion with protei-
nase K, followed by a second round of proteinase K
digestion, and then heat inactivation was performed.
Screening for LOH was carried out by polymerase
chain reaction (PCR) followed by Sanger dideoxy
sequencing [25] or missense and nonsense alterations,
while denaturing capillary analysis was performed for
insertions and deletions. Exon specific oligonucleotide
primers flanking known BRCA1 mutations were
designed using Primer3 software [26] and limited to a
maximum product size of 200 base pairs in order to
successfully amplify sheared DNA extracted from paraf-
fin embedded tissue (sequences listed in Additional file
1). PCR primers were ordered [27] with universal
sequence tags at the 5’ end in order to allow for second-
ary amplification, sequencing with a universal primer
and elimination of primer dimers.
For cancers with missense and nonsense mutations,
bidirectional DNA sequencing in triplicate was per-
formed using BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA) and uni-
versal primers. Purified sequencing products were ana-
lyzed in 3730xl DNA Analyzers (Applied Biosystems).
Sequence data from triplicate forward and reverse reac-
tions from each micro-dissected tumor and normal sur-
rounding tissue were analyzed using the Mutation
Surveyor program version 3.30 (SoftGenetics, State Col-
lege, PA, USA). The NM_Score is a value assigned to
each nucleotide in a sequencing chromatogram. This
score is used to determine mutant allele contribution
based on shape and height at each position in the
sequence. Normal (that is, non-cancerous) tissue DNA
from BRCA1 carriers is generally heterozygous for
BRCA1 mutation, and therefore sequence NM_scores
are less than 1.5 indicating a significant difference from
homozygous wild-type. In tumors with LOH and loss of
the wild type allele, the difference from homozygous
wild-type becomes even more significant as the
NM_score decreases further towards 0.
Analysis of LOH in tumors with insertions or dele-
tions in BRCA1 was performed by taking advantage of
the difference in size of the wild type and mutant alleles.
Primary amplification was performed using the same
conditions described for sequencing analysis above. Sec-
ondary PCR amplification was used to add a 6-FAM
fluorescent label onto the 5’-end of the primary PCR
products. Reaction products were then analyzed on
ABI3730XL (Applied Biosystems) instruments using
POP7 denaturing polymer (Applied Biosystems). The
relative height of the wild type and mutant peaks was
measured using Dax software (Van Mierlo Software
Consultancy, Eindhoven, NL) and was used to indicate
LOH. An example of the data for 187delAG analysis is
shown in Additional file 2. Further details of the metho-
dology used for LOH determination are included in
Additional file 3[28-30].
Analysis of BRCA1 promoter methylation
Tumor DNA was subjected to bisulfite modification
using EZ DNA methylation-gold kit (Zymo Research,
Orange, CA, USA). Lymphocyte DNA treated with Sss
bacterial methylase (New England BioLabs, Ipswich,
MA, USA) was used as a positive control. Lymphocyte
DNA treated with bisulfite served as a negative control.
Bisulfite treated tumor DNAs were analyzed by methyla-
tion specific PCR for BRCA1 promoter as in Matros et
al. [31]. The methylation assay evaluates CpG sites
within the BRCA1 promoter at positions -37, -29, -21,
-19 from the start site. PCR products were resolved by
3% agarose gel electrophoresis.
Statistics
Determination of cutoff values for LOH
Tumors with insertion/deletion mutations The per-
centage of mutant BRCA1 DNA (mutant BRCA1 DNA/
mutant plus wt BRCA1 DNA; m%) was determined by
comparing peak heights specific for normal and mutant
alleles determined from DNA extracted from each
microdissected sample of normal tissue and tumor tis-
sue. PCR reactions were run in triplicate for each micro-
dissected normal and tumor tissue sample and those
samples with three successful amplifications were
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tion (CV) of the triplicate m% and 100-m% values were
calculated for each microdissected sample and those
with a CV greater than 20% were not considered
further. For each microdissected sample, the average m
% from the triplicate PCR reactions was determined. If
multiple microdissected samples from a single tumor all
showed acceptably low m% CV’st h e nt h er e s u l t sf r o m
the separate microdissections were averaged to give a
single average m% for that tumor or normal specimen.
Determination of LOH for BRCA1 was guided by the
assumption that the majority of normal tissue specimens
should not have LOH, though there are data that some
lobules from normal appearing breast tissue obtained
from BRCA1 carriers undergoing prophylactic mastec-
tomies can have LOH with loss of wt BRCA1 [32]. Two
different strategies were adopted to determine the
optimal m% cut-off for a determination of LOH. First,
logistic regression was used to optimally discriminate
between tumor and normal tissue yielding cut-off values
for LOH. For this computation all specimens were
assumed to be independent. In the second approach, the
range of average m% values was determined for all the
adjacent normal tissues dissected from tumors with
insertion or deletion mutations. The 95% CI for average
m% for normal tissue was determined within two stan-
dards of deviations. Tumors with an average m% above
the upper limits of this 95% CI were determined to have
LOH with loss of wt BRCA1 and tumors with average
m% below the limits of the 95% CI were determined to
have LOH with loss of the mutant BRCA1 allele (LOH-
mut). Both methods yielded virtually identical results. An
average m% > 60 was considered to represent LOH with
loss of wt BRCA1 a n dm %<4 0w a sc o n s i d e r e dt o
represent LOH
mut in the 59 cancers with small inser-
tions or deletions.
The 1294del40 mutation results in a 40 bp deletion.
The significant difference in size between the PCR pro-
ducts from the normal allele vs. the deletion mutant
allele results in preferential amplification of the smaller
mutant allele and a skewed ratio of mutant to normal
PCR products. Therefore, the determination of LOH
cut-off was performed separately for the 1294del40
mutations using the same process described above con-
sidering both the distribution of m% in normal
1294del40 heterozygous tissu e sa sw e l la si n s i g h tf r o m
logistic regression. An average m% of > 85 was estab-
lished as an appropriate cut-off for determining loss of
wt BRCA1 for the 1294del40 cases.
Tumors with missense and nonsense mutations For
cases with missense and nonsense mutations, the
NM_Score (generated by the Mutation Surveyor pro-
gram) was used to determine LOH. NM_scores from
the forward sequencing triplicate data and reverse
sequencing triplicate data were averaged separately for
each case due to base and strand specific variation in
the score. Samples with forward and reverse triplicate
NM_score measurements showing a CV < 20% were
included. Multiple microdissected samples from a single
tumor with acceptably low NM_score CV’sw e r ea v e r -
aged to give a single average NM_score for that case.
The same process described above using logistic regres-
sion as well as 95% CI for normal tissue NM_score was
used to determine the LOH cutoff for the 14 cancers
with missense or nonsense mutations. An NM_score of
< 0.6 was deemed to represent LOH with loss of wt
BRCA1 and NM_score > 1.4 was interpreted as LOH
mut.
Predictors of loss of wt BRCA1
The Wilcoxon Rank Sum test was used to determine
P-value differences in mean age between BRCA1 first
invasive breast cancers with and without loss of wt
BRCA1. The two-sided Fisher exact test was used to
determine differences in the frequency of variables
between cancers with and without loss of wt BRCA1 on
univariate analysis. The Bonferroni calculation identified
P < 0.003 as significant after correction for multiple
comparisons. In the multivariate analyses, exact logistic
regression was used to evaluate the association between
loss of wt BRCA1 and the variables found significant in
the univariate analyses. For these analyses, the cases
with LOH and loss of wt BRCA1 were compared to the
combined group of cases showing either no LOH or
LOH
mut.
Results
Prevalence of loss of wt BRCA1
Ninety-eight BRCA1-associated ER+ and ER- invasive
breast cancers were used for this analysis. Of the 98 ER
+ and ER- breast cancers from women with BRCA1
mutations, the status of the wt BRCA1 allele could not
be obtained for 21 cancers (12 ER- and 9 ER+): in 4
cancers (1 ER- and 3 ER+), microdissection for isolation
of a pure population of tumor cells was not feasible due
to the intimate admixture of single tumor cells and nor-
mal cells; in 10 cancers (8 ER- and 2 ER+) PCR failed;
in 7 cancers (3 ER- and 4 ER+) the results from tripli-
cate PCR were too variable (that is, CV > 20%) for
inclusion in analysis.
Thus, reliable determination of the status of the wt
BRCA1 allele was possible in 77 BRCA1-associated
breast cancers (42 ER+, 35 ER-). Of these cancers 34/42
(81.0%) ER+ and 31/35 (88.6%) ER- had LOH with loss
of the wt BRCA1 allele; the difference in frequency of
loss of wt BRCA1 between ER+ and ER- cancers was
not significant (P = 0.53).
Six cancers (three ER+ and three ER-) with insertion/
deletion mutations had m% < 40% and one cancer (ER
+) with a point mutation had an NM score > 1.4
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allele. In sporadic breast cancers, particularly in ER-
cancers, loss of heterozygosity involving large regions of
chromosome 17, including the BRCA1 locus, is seen in
49 to 57% of cases [33-35]. In the BRCA1-associated
cancers in this study, LOH with loss of either the wt or
mutant BRCA1 allele was observed in 97% of ER- and
90% of ER+ cases. If LOH involving this region was
unrelated to the BRCA1 mutation, loss of the wt and
mutant alleles would be expected to occur with equal
frequencies. As shown in Additional file 4, the observed
frequencies of loss of the wt and mutant alleles, deter-
m i n e db yc h i - s q u a r et e s t ,a r es i g n i f i c a n t l ys k e w e d
toward loss of wt BRCA1 (P < 0.001). There was no
relationship between ER status and distribution of which
allele was lost by LOH (P = 0.81). This result demon-
strates the non-random relationship between LOH and
selection for loss of wt BRCA1 in both ER+ and ER-
BRCA1-associated tumors.
The distribution of m% values for normal and tumor
samples (both ER+ and ER-) from insertion/deletion
analysis are shown in Figure 1a. The mean and standard
deviation of percent mutant allele from analysis of nor-
mal tissues was 50% ± 8.3%, indicating the expected
proportion of mutant and wt alleles in heterozygous
samples. The distribution of retained NM_scores from
normal and ER+/ER- tumor samples with missense or
nonsense mutation are shown in Figure 1b. The distri-
butions for m% and NM_score for ER+ and ER-
BRCA1-associated cancers were roughly similar. Several
cases (seven ER- and two ER+) were noted to have an
m% between 60 and 80%. Assuming a pure tumor sam-
ple, this intermediate level of mutant allele may indicate
intratumoral heterogeneity for LOH, with an admixture
of tumor cells with and without LOH. Alternatively,
intermediate m% values may represent samples with
slightly more normal cell contamination as an absolutely
pure tumor sample is not always attainable, even with
microdissection. Without performing an in situ LOH
assay, it is not possible to distinguish these alternative
explanations for any differences in distribution observed
between ER+ and ER- cancers.
While the spectrum of BRCA1 mutations was varied
in this group of 77 cancers, 57% of the mutations were
Ashkenazi mutations (Additional file 5) reflecting the
significant Jewish population in the communities served
by the participating hospitals. Fifty-nine cancers
occurred in women with a small BRCA1 insertion or
deletion mutation, four additional women had a large 40
base-pair deletion (1294del40), seven had nonsense
point mutations and three had a splice site mutation
resulting in an in-frame deletion of an exon. Only four
women had missense point mutations. Of the 12 cancers
without loss of wt BRCA1,1 0( 4E R - ,6E R + )h a d
protein truncating lesions and 2 (both ER+) had a splice
site mutation resulting in an in-frame deletion (Addi-
tional file 5). Specific mutations for each cancer as well
as the percentage of mutated BRCA1 DNA (m%),
NM_score, and ER status for each cancer is shown in
Additional file 5.
Clinical, pathologic and immunohistochemical findings
All BRCA1-associated breast cancers (ER+ and ER-
combined)
When pathologic features and biomarkers expression of
all BRCA1-associated cancers (ER+ and ER- combined)
were analyzed according to status of loss of wt BRCA1
allele, in univariate analysis, breast cancers with loss of
wt BRCA1 were more likely to be of pure invasive ductal
type (P = 0.043), to be histologic grade 3 (P = 0.001), and
to have a higher mitotic rate (P < 0.001) (Table 1). Can-
cers with loss of wt BRCA1 were also more likely to exhi-
bit expression for CK5/6 (P < 0.001), CK14 (P = 0.023) or
e i t h e rC K 5 / 6o rC K 1 4( P <0 . 0 0 1 )( T a b l e1 ) .C a n c e r s
with loss of wt BRCA1 were more likely to express either
CK5/6 or CK14 even after Bonferroni adjustment for
multiple comparisons and in multinomial logistic regres-
sion (odds ratio (OR), 4.7; 95% CI, 1.85 to ∞).
H E R 2p r o t e i no v e r e x p r e s s i o na n d / o rg e n ea m p l i f i c a -
tion was found in four of the 77 BRCA1-associated
breast cancers (one by IHC; three by FISH). Two of the
three HER2 FISH amplified tumors did not show loss of
wt BRCA1. The HER2 overexpressing tumor identified
by IHC did demonstrate LOH for wt BRCA1; however,
material was not available to analyze this case for HER2
gene amplification by FISH.
We also compared the frequency of pathologic fea-
tures and biomarker expression of the 12 ER- and 9 ER
+ BRCA1-associated cancers for which wt BRCA1 allele
status could not be determined to ensure that this
group was similar to those cancers which were success-
fully subjected to LOH analysis. No significant differ-
ences in any of the pathologic features or biomarkers
were identified between the groups with and without
successful BRCA1 LOH analysis.
ER+ BRCA1-associated cancers
The age at which first ER+ breast cancers developed was
analyzed according to wt BRCA1 allele status. The mean
age at diagnosis was 45.2 years for the 24 ER+ first
breast cancers with loss of wt BRCA1, compared to 50.1
years in those 8 ER+ first cancers that retained a wt
BRCA1 allele. This difference was not statistically signifi-
cant (P = 0.51) (Table 2).
T h ep a t h o l o g i cf e a t u r e so ft h eE R +BRCA1 cancers
with (n = 34) and without (n =8 )l o s so fw tBRCA1 are
compared in Table 2. In univariate analysis, those ER+
BRCA1 cancers retaining wt BRCA1 more often had a
low mitotic rate (100% vs 27%; P < 0.001), were less
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Figure 1 The distributions of the percent mutant allele are similar for ER+ and ER- BRCA1-associated breast cancers.T h ef r e q u e n c y
distributions of percent mutant allele (m% values) for cases with insertion or deletion mutations in BRCA1 but excluding 1294 del40 cases (a)
and the frequency distributions of NM_scores for cases with missense or nonsense point mutations (b) are shown for adjacent normal tissue
samples (pink), ER+ tumor samples (blue), and ER- tumor samples (green). Distributions are calculated using all triplicate measurements from
those samples passing quality assessment (that is, CV < 20%). In panel A, higher m% values indicate LOH with loss of wt BRCA1 allele (LOH
wt)
and lower values indicate LOH with loss of mutant BRCA1 allele (LOH
mut). For panel B, lower NM_scores indicate loss of wt BRCA1 and higher
NM_scores indicate loss of mutant BRCA1.
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and less often grade 3 (0% vs 68%; P <0 . 0 0 1 ) .T h ed i f -
ferences in mitotic rate and grade retained significance
even after Bonferroni adjustment. In multinomial logis-
tic regression, ER+ BRCA1-associated cancers retaining
wt BRCA1 were significantly more likely than cancers
without wt BRCA1 to have a low mitotic rate (OR, 5.16;
95% CI, 1.91 to ∞).
Results of biomarker studies were available for most of
the BRCA1-associated cancers (Table 3). None of the eight
ER+ cancers that retained wt BRCA1 showed expression
of basal cytokeratins CK5/6 or CK14. In contrast, 11 of 33
ER+ cancers with loss of wt BRCA1 (33.3%) showed
expression for one or the other of these basal cytokeratins.
However, this difference was not statistically significant,
possibly due to the small number of cases.
ER- BRCA1-associated cancers
In ER- cancers, the mean age at diagnosis of first inva-
sive cancers with or without loss of wt BRCA1 was 42
years and 33.5 years, respectively. This difference was
not statistically significant (P = 0.15) (Table 2).
No significant histopathologic differences were noted
between the 31 ER- cancers with loss of wt BRCA1 and
the 4 ER- cancers with retention of wt allele. Like the
ER- cancers with loss of wt BRCA1, the four ER- can-
cers retaining wt BRCA1 were high grade ductal cancers
with a high mitotic rate. There were also no significant
differences between tumors with or without loss of wt
BRCA1 with regard to those features considered to be
characteristic of ER- BRCA1-associated cancers, includ-
ing geographic necrosis, pushing margins, and moder-
ate-marked lymphocytic infiltrate (Table 2).
There were significant differences in the frequency of
expression of basal cytokeratins CK5/6 and CK14 in ER-
cancers with and without loss of wt BRCA1 in univariate
analysis (Table 3). Expression of either CK5/6 or CK14
was significantly more frequent in the 27 ER- cases with
loss of wt BRCA1 compared to the 4 cases without (89%
Table 1 Pathologic and immunohistochemical characteristics that were significantly different in BRCA1-associated
breast cancers with and without loss of wt BRCA1
Variables Loss of wt BRCA1 No loss of wt BRCA1 P-value
N(%) N(%)
Sample Size 65 12
Histology
Ductal* 59 (90.8) 8 (66.7) 0.043
Ductal/Lobular 4 (6.1) 3 (25)
Other 2 (3.1) 1 (8.3)
Mitoses/10 high power field
0 to 5* 10 (15.4) 8 (66.7) < 0.001*
6 to 10 14 (21.5) 0
> 10 41 (63.1) 4 (33.3)
Grade
1 (3 to 5 points) 5 (7.7) 5 (41.7)
2 (6 to 7 points) 7 (10.8) 3 (25)
3 (8 to 9 points)* 53 (81.5) 4 (33.3) 0.001*
CK5/6 58 11
Positive 29 (50) 0 (0) < 0.001*
Negative 29 (50) 11 (100)
CK14 58 9 0.023
Positive 23 (39.7) 0
Negative 35 (60.3) 9 (100)
CK5/6 or CK14 60 12 < 0.001*
Positive 35 (58.3) 0 ((0)
Negative 25 (41.7) 12 (100)
CK5/6 and/or CK14 and/or EGFR 61 12 0.023
Positive 39 (63.9) 3 (25)
Negative 22 (36.1) 9 (75)
Abbreviations: ER, estrogen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor.
Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
No loss of wt: includes cancers with no LOH and LOH
mut.
*P-value retained significance with Bonferroni adjustment for multiple comparisons.
Percentages calculated by column.
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Page 7 of 13Table 2 Pathologic characteristics and their association with loss of wt BRCA1 in ER-positive and ER-negative BRCA1-
related breast cancers
Variable ER+ ER-
Loss of wt
BRCA1
N(%)
No loss of wt
BRCA1
N(%)
P-value Loss of wt BRCA1 N
(%)
No loss of wt
BRCA1
N(%)
P-
value
Sample Size 34 8 31 4
First cancers 24 (70.6) 8 (100) 28 (90.3) 2 (50)
Mean age (range) 45.2 (29 to 68) 50.1 (33 to 72) 0.51 42 (28 to 73) 33.5 (31 to 36) 0.14
Second cancers 10 (29.4) 0 3 (9.7) 2 (50)
Mean age (range) 48.7 (34 to 63) 56 (53 to 61) 57 (56 to 58)
Histology
Ductal* 29 (85.3) 4 (50) 0.05 30 (96.8) 4 (100) 1.00
Ductal/Lobular 3 (8.8) 3 (37.5) 1 (3.2) 0
Other 2 (5.9) 1 (12.5) 0 0
Mitoses/10 high power field
0 to 5* 9 (26.5) 8 (100) < 0.001* 1 (3.2) 0 1.00
6 to 10 12 (35.3) 0 2 (6.5) 0
> 10 13 (38.2) 0 28 (90.3) 4 (100)
Grade
1 (3 to 5 points) 5 (14.7) 5 (62.5) 0 0
2 (6 to 7 points) 6 (17.6) 3(37.5) 1 (3.2) 0
3 (8 to 9 points)* 23 (67.6) 0 < 0.001* 30 (96.8) 4 (100) 1.00
Geographic Necrosis/Fibrotic
Focus
Yes 9 (26.5) 0 1.00 22 (71.0) 2 (50) 0.574
No 25 (73.5) 8 (100) 9 (29.0) 2 (50)
Margins
Invasive 29 (85.3) 8 (100) 1.00 15 (48.4) 2 (50) 1.00
Pushing/Circumscribed 5 (14.7) 0 16 (51.6) 2 (50)
Lymphocyte Infiltrate
Moderate/Severe 4 (11.8) 0 1.00 13 (41.9) 2 (50) 1.00
None/Mild 30 (88.2) 8 (100) 18 (58.1) 2 (50)
PR
Positive* 29 (85.3) 8 (100) 1.00 1 (3.6) 0 1.00
Positive 26 (76.5) 7 (87.5) 0
Low Positive
a 3 (8.8) 1 (12.5) 1 (3.6)
Negative 5 (14.7) 0 27 (96.4) 4 (100)
Unknown 0 0 3 (9.8) 0
Her2/Neu IHC
Positive 1 (2.9) 0 1.00 0 0 1.00
Negative 24 (70.6) 7 (87.5) 25 (80.6) 3 (75)
Her2/Neu FISH
Positive 1 (2.9) 1 (12.5) 0 1 (25)
Negative 6 (17.6) 0 5 (16.1) 0
Equivocal
d 2 (5.9) 0 1 (3.2) 0
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
No loss of wt: includes cancers with no LOH and LOH
mut .
Percentages calculated by column.
a Low PR positive: 1 to 10% cells show nuclear staining for PR.
b HER2 positive: HER2:CEP17 ratio by FISH > 2.2 or IHC 3+ (no FISH performed).
c HER2 negative: HER2:CEP17 ratio by FISH < 1.8 or IHC < 3+ (no FISH performed).
d HER2 equivocal: HER2:CEP17 ratio by FISH 1.8 to 2.2.
* P-value retained significance with Bonferroni adjustment for multiple comparisons.
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Page 8 of 13vs. 0%, P = 0.001). This difference was significant even
after Bonferroni correction. In multinomial logistic
regression, ER- cancers with loss of wt BRCA1 were sig-
n i f i c a n t l ym o r el i k e l yt os h o we x p r e s s i o no fC K 5 / 6o r
CK14 (OR 5.48; 95% CI 1.79 to ∞). There were no signif-
icant differences in EGFR or p53 expression between ER-
cancers with and without loss of wt BRCA1 (Table 3).
BRCA1 methylation
BRCA1 promoter methylation is a potential alternative
mechanism to LOH for providing the “second hit” to
inactivate wt BRCA1 in BRCA1-associated cancers.
BRCA1 promoter methylation analysis was performed
by methylation-specific PCR on 28 cases for which
remaining tumor DNA was available, including 6 of the
8 ER+ and 3 of the 4 ER- cancers which did not
demonstrate loss of wt BRCA1. Methylation was identi-
fied in a single tumor sample, an ER+ low-grade (tubu-
lar) carcinoma without genomic loss of wt BRCA1.
Discussion
In this study, we found that 81.0% of ER+ BRCA1-
associated breast cancers showed LOH with loss of the
wt BRCA1 allele. The prevalence of loss of wt BRCA1
in these ER+ tumors was similar to that seen in the
ER- BRCA1-associated cancers (88.6%). This is the first
study, to our knowledge, that has specifically examined
loss of wt BRCA1 in a large cohort of BRCA1-asso-
ciated breast cancers in relation to ER status. Our
results are consistent with those reported in previous
smaller studies [22-24]. Only two of these prior studies
Table 3 Immunohistochemical characteristics and their association with loss of wt BRCA1 in ER-positive and ER-
negative BRCA1-related breast cancers
Variable ER+ ER-
Loss of wt BRCA1
N(%)
No loss of wt BRCA1
N(%)
P-value Loss of wt BRCA1
N(%)
No loss of wt BRCA1
N(%)
P-value
Cytokeratins
CK5/6 (31) (7) 0.164 (27) (4) 0.010
Positive 9 (29.0) 0 20 (74.1) 0
Negative 22 (71.0) 7 (100) 7 (25.9) 4 (100)
CK7/8 (31) (8) — (28) (4) 1.0
Positive 31 (100) 8 (100) 25 (89.3) 4 (100)
Negative 0 0 3 (10.7) 0
CK14 (31) (6) 0.566 (27) (3) 0.054
Positive 5 (16.1) 0 18 (66.7) 0
Negative 26 (83.9) 6 (100) 9 (33.3) 3(100)
CK5/6 or CK14 (33) (8) 0.083 (27) (4) 0.001*
Positive 11 (33.3) 0 24 (88.9) 0
Negative 22 (66.7) 8 (100) 3 (11.1) 4 (100)
CK 18 (32) (7) —— (27) (4) 1.00
Positive 32 (100) 7 (100) 26 (96.3) 4 (100)
Negative 0 0 1 (3.7) 0
CK19 (33) (6) —— (28) (4) 0.125
Positive 33 (100) 6 (100) 28 (100) 3 (75)
Negative 0 0 0 1 (25)
EGFR (30) (7) 0.560 (26) (4) 0.360
Positive 5 (16.7) 0 24 (92.3) 3(75)
Negative 25 (83.3) 7 (100) 2 (7.7) 1 (25)
CK5/6 and/or CK14 and/or EGFR (33) (8) 0.083 (28) (4) 0.125
Positive 11 (33.3) 0 28 (100) 3 (75)
Negative 22 (66.7) 8 (100) 0 1 (25)
P53 (30) (7) 1.00 (26) (4) 0.601
Positive 14 (46.7) 4 (57.1) 13 (50) 3 (75)
Negative 16 (53.3) 3 (42.9) 13 (50) 1 (25)
Abbreviations: ER, estrogen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor.
Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
No loss of wt: includes cancers with no LOH and LOH
mut .
*P-value retained significance with Bonferroni adjustment for multiple comparisons.
Percentages calculated by column.
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Page 9 of 13included any ER+ BRCA1 cancers and reported loss of
wt BRCA1 in 75% and 83% of such cancers [22,24].
Only one cancer of the 28 evaluated in our study
demonstrated BRCA1 promoter methylation, an ER+
cancer with retention of wt BRCA1. These results are
consistent with the lower cumulative methylation
observed in BRCA1-associated cancers compared to
sporadic cancers [36]. Our results are also comparable
to those of Dworkin et al. who found that none of
seven of their BRCA1 cancers without LOH showed
methylation as a “second hit” [22]. The one ER+ cancer
demonstrating BRCA1 methylation in our series was not
typical of the ER+ cancers with loss of wt BRCA1, being
a low grade (tubular) carcinoma with a low mitotic rate.
Studies of sporadic breast cancers have not found repro-
ducible associations between BRCA1 promoter methyla-
tion and tumor phenotype [31,37]. Furthermore, somatic
methylation may be related to increasing age in some
cases [36,38]. BRCA1 promoter methylation has been
found in germline DNA in five to seven percent of indi-
viduals regardless of health or BRCA1/2 status and
showed no association with development of breast can-
cer [39]. Whether the BRCA1 promoter methylation
found in the tumor DNA of the one patient in our ser-
ies is indicative of loss of wt BRCA1 function is uncer-
tain and its clinical significance is unclear.
Previously, we have described that ER+ BRCA1-asso-
ciated cancers are more often high grade ductal cancers
compared to age matched ER+ sporadic breast cancers
[20]. Our current findings that ER+ cancers with loss of
wt BRCA1 are significantly more often higher grade can-
cers is a consistent extension of our original results.
Interestingly, a recent study found that ER+ cancers
which develop in BRCA2 carriers are of higher grade
than age matched ER+ sporadic cancers [40]. Combined
with our data, it appears that loss of BRCA1 or BRCA2
function results in a more proliferative luminal cancer
when an ER+ cancer develops.
It has been suggested that basal-like cytokeratin expres-
sion in triple negative tumors is a good predictor of
BRCA1 mutation status [7]. Rakha et al.[ 4 1 ]e x a m i n e d
seventeen BRCA1-associated ER-, HER2- breast cancers
and found that only one of seventeen (5.9%) did not
show expression of either CK5/6 or EGFR, also consid-
ered to be a basal marker. To distinguish between those
ER- BRCA1-associated breast cancers that did or did not
have loss of the wt BRCA1 allele, however, we found the
combination of CK5/6 and CK14 most useful. Adding
EGFR staining increased the sensitivity of identifying ER-
cancers with loss of wt BRCA1 (28/28; 100%), however it
lowered the specificity as three of four of the ER- cancers
without loss of wt BRCA1 (75%) stained for EGFR.
Immunostains were less helpful in distinguishing ER+
cancers with and without loss of the wt BRCA1 allele. It
is noteworthy that none of the ER+ cancers that
retained wt BRCA1 expressed CK5/6 or 14, while the
only ER+ cancers expressing these basal cytokeratins
had lost wt BRCA1. However, as the majority of the ER
+ cancers with loss of wt BRCA1 did not express either
basal cytokeratin, this difference was not significant. Lar-
ger studies are necessary to explore the possibility that
basal epithelial markers may mark ER+ cancers that
have lost wt BRCA1.
Our results regarding HER2 overexpression/gene
amplification in BRCA1-associated cancers are consis-
tent with prior studies that have found that HER2 over-
expression and amplification are uncommon in these
tumors [5,6,42]. In the 77 BRCA1 cancers we studied,
only one BRCA1-associated cancer with loss of wt
BRCA1 demonstrated HER2 gene amplification by FISH.
There may be mechanisms other than LOH or methy-
lation by which the wt BRCA1 allele is inactivated in
BRCA1- a s s o c i a t e dc a n c e r sw h i c hw e r en o te x a m i n e di n
this study (for example, somatic mutation of the second
allele elsewhere in the BRCA1 gene or ID4 modulation
of BRCA1 expression [37,43]). However, significant phe-
notypic differences were observed between ER+ cancers
with or without loss of wt BRCA1. Assuming phenotype
is linked to gene function, these phenotypic differences
suggest that ER+ cancers with a wt BRCA1 allele are
likely to also have retained BRCA1 function and have
not inactivated wt BRCA1 by an alternative mechanism.
It has been previously reported that ER+ breast can-
cers are more likely to develop in BRCA1 carriers as
they age, suggesting that some of these may be inciden-
tal breast cancers occurring in BRCA1 carriers. How-
ever, we did not see a significant difference in age at
diagnosis between first ER+ breast cancers with and
without loss of wt BRCA1. In addition all 10 ER+ sec-
ond cancers that developed in BRCA1 carriers demon-
strated loss of wt BRCA1. It is possible that these
findings are due to limited numbers, but it is also possi-
ble that some mechanism other than incidental develop-
ment of breast cancer, with functioning wt BRCA1,i s
needed to explain why the development of ER+ breast
c a n c e r si sm o r ec o m m o na sBRCA1 mutation carriers
age.
Further, it is apparent that the presence of wt BRCA1
is not required for ER expression in cancer tissues, in
contrast to what has been suggested by some preclinical
studies [16]. Other studies have proposed wt BRCA1 is
essential for differentiation of mammary stem cells to
ER+ luminal cells and that loss of wt BRCA1 causes an
expansion of ER-negative mammary stem cells, offering
am e c h a n i s mf o rt h ec o m m o nE R - n e g a t i v i t yo fBRCA1
breast cancers [32]. However, this model does not
address the origin of ER+ BRCA1-associated breast can-
cers. Another recent study has found expansion of a
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Page 10 of 13committed luminal progenitor population, containing
both ER+ and ER- cells, in preneoplastic tissues of
BRCA1 mutation carriers and proposed the luminal pro-
genitor cells as the cell of origin of BRCA1-associated
cancers [44]. In mouse models of tumorigenesis pro-
duced by deletion of BRCA1, the expression of ER in
the resulting tumors appears to depend on whether
BRCA1 is deleted at an earlier or later stage of cell dif-
ferentiation [32,45,46]. Our findings are consistent with
these models and suggest that BRCA1-deficient ER+
tumors may derive from BRCA1 loss in an ER-positive
luminal progenitor cell.
This study cannot resolve whether ER+ breast cancers
without loss of wt allele that develop in BRCA1 carriers
are equivalent to ER+ sporadic breast cancers that occur
in non-carriers. It is possible that no breast cancer that
develops in a BRCA1 mutation carrier is really “inciden-
tal” or sporadic even if one functioning wt BRCA1 allele
is retained and expressed. Haploinsufficiency of BRCA1
may predispose both to the development of breast can-
cer as well as to a specific histopathologic and or immu-
nohistochemical profile. However, testing for differences
between BRCA1-associated ER+ cancers with a retained
wt BRCA1 and ER+ sporadic breast cancers would
require larger numbers of these ER+ BRCA1 cancers as
well as age matched ER+ sporadic controls.
Conclusions
In conclusion, in this study of 77 BRCA1-associated
breast cancers, we found similar frequencies of LOH
with loss of wt BRCA1 in ER+ and ER- breast cancers.
In addition, loss of wt BRCA1 results in higher grade
ductal cancers with higher proliferative rates, and a
greater propensity to express basal cytokeratins. Many
of the new therapies being evaluated in BRCA1 breast
cancers, such as poly(ADP-ribose) polymerase (PARP)
inhibitors and cisplatin [47,48], are designed to take
advantage of the defect in homologous recombination
that BRCA1 deficiency causes in these cancers. The
results of our study suggest that allele-specific LOH ana-
lysis to evaluate for loss of wt BRCA1 is more likely to
predict response to such therapies than estrogen recep-
tor expression. In addition to family history and age of
onset, identification of women who may carry a pre-
viously undetected BRCA1 mutation has recently
focused on the triple negative subset as a population
enriched for BRCA1 mutation carriers. Our results sug-
gest that the high grade ER+ luminal cancers also may
be enriched for tumors with BRCA1 or BRCA2 defi-
ciency. A concerted effort should be made to identify
these women so that they are not deprived of potentially
effective new therapies.
Additional material
Additional file 1: Sequence Primers. Sequences of primers used to
amplify the regions surrounding each mutation analyzed in the study are
provided.
Additional file 2: Indel Analysis by denaturing capillary
electrophoresis. An example of loss of the wt BRCA1 allele (LOHwt) in a
tumor from a patient with a 187delAG mutation is provided.
Additional file 3: Supplementary methods. Additional information
describing the methodology used to determine LOH is supplied.
Additional file 4: Distribution of allele loss in tumors with LOH. This
table presents the observed compared to the expected frequencies of
loss of the wt and mutant BRCA1 alleles in ER+ and ER- BRCA1 breast
cancers analyzed.
Additional file 5: LOH result for ER+ and ER- BRCA1-associated
breast cancers analyzed. For each breast cancer analyzed, the following
associated features are presented: specific mutation; age at diagnosis; ER
status; m% or NM_score; LOH result; and BRCA1 promoter methylation.
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